ProCE Banner Activity

Expert Perspective on Key Trial Updates in Treatment of CLL: What You Need to Know From ASCO/EHA/ICML 2021

Clinical Thought
Gain clinical perspectives from an internationally recognized expert on key data in CLL from the 2021 ASCO, EHA, and ICML virtual meetings.

Released: September 17, 2021

Expiration: September 16, 2022

No longer available for credit.

Share

Faculty

George Follows

George Follows, BM, BCh, PhD

Visiting Professor of Haematology
Department of Haematology
Anglia Ruskin Medical School
Consultant Haematologist
Department of Haematology
Cambridge University Hospitals
Cambridge, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

George Follows, BM, BCh, PhD

Visiting Professor of Haematology
Department of Haematology
Anglia Ruskin Medical School
Consultant Haematologist
Department of Haematology
Cambridge University Hospitals
Cambridge, United Kingdom

George Follows, BM, BCh, PhD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Celgene, Janpix, Janssen, Karyopharm, Kite, and Roche; has received fees for non-CME/CE services from AbbVie, AstraZeneca, Janssen, and Roche; and has ownership interest in Janpix.